Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids.
The primary objective of this study is to demonstrate the superior efficacy versus placebo of BG2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Uterine Fibroids|Heavy Menstrual Bleeding
DRUG: BG2109|DRUG: Placebo for BG2109|DRUG: Placebo for add-back therapy|DRUG: Add-back therapy
Percentage of Responders based on menstrual blood loss (MBL) volume reduction at Week 24., MBL will be determined using the Alkaline Hematin method (AHM). Responder means whose MBL less than 80mL during the last 28 days before the Week 24 and more than 50% reduction in MBL compared to the baseline., The last 28 days before the Week 24.
Time to reduced MBL before the Week 24., Reduced MBL means MBL less than 80ml and more than 50% reduction in MBL compared to the baseline., From baseline to Week 24.|Percentage of amenorrhea at the Week 24., Amenorrhea is defined as having 0 data (or volume below the lower limit of quantification) from the AHM of MBL from the central laboratory or missing of AHM data with reported of "spotting" or "no bleeding" in the eDiary for 35 days before Week 24., From baseline to Week 24.|Time to amenorrhea before the Week 24., The number of days from Study Day 1 to the first day having amenorrhea., From baseline to Week 24.|Days of menstrual bleeding in the last 28 days before the Week 24., Record the number of days., The last 28 days before the Week 24.|Hemoglobin levels at the Week 24 in the subgroup of subjects with anemia., Anemia is defined as hemoglobin below 12g/dL at baseline., The Week 24.
Percentage of Responders at the Week 52., Responder is defined as above., The last 28 days before the Week 52.|Time to reduced MBL before the Week 52., Reduced MBL is defined as above., From baseline to Week 52.|Percentage of amenorrhea at the Week 52., Amenorrhea is defined as above., From baseline to Week 52.|Time to amenorrhea before the Week 52., The number of days from Study Day 1 to the first day having amenorrhea., From baseline to Week 52.|By 52 weeks, the number of days with menstrual bleeding per 28 days., Record the number every 28days., From baseline to Week 52.|Score of Uterine Fibroids related pain, symptoms and quality of life., Use specified scales., From Week 12 to Week 64|Bone Mineral Density (BMD), Assessed by dual-energy X-ray absorptiometry (DXA) scan., The Week 24 and Week 52.|Adverse events, Clinical manifestationï¼Œfrequency and severity of Treatment-Emergent Adverse Events., Up to Week 64.
The study is a prospective, randomized, parallel group, double-blind, placebo-controlled phase 3 study investigating the efficacy and safety of BG2109 alone and in combination with add-back therapy (Estradiol 1 mg / Norethindrone Acetate 0.5 mg) for the treatment of uterine fibroids in China.